An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]

被引:131
|
作者
Garrison, Louis P., Jr. [1 ]
Pauly, Mark V. [2 ]
Willke, Richard J.
Neumann, Peter J. [3 ]
机构
[1] Univ Washington, Sch Pharm, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA
[2] Univ Penn, Wharton Sch, Hlth Care Management, Philadelphia, PA 19104 USA
[3] Tufts Med Ctr, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
关键词
cost-effectiveness analysis; decision context; perspective; value; COST-EFFECTIVENESS; VALUE FRAMEWORK; GUIDELINES;
D O I
10.1016/j.jval.2017.12.006
中图分类号
F [经济];
学科分类号
02 ;
摘要
The second section of our Special Task Force builds on the discussion of value and perspective in the previous article of the report by 1) defining a health economics approach to the concept of value in health care systems; 2) discussing the relationship of value to perspective and decision context, that is, how recently proposed value frameworks vary by the types of decisions being made and by the stakeholders involved; 3) describing the patient perspective on value because the patient is a key stakeholder, but one also wearing the hat of a health insurance purchaser; and 4) discussing how value is relevant in the market-based US system of mixed private and public insurance, and differs from its use in single-payer systems. The five recent value frameworks that motivated this report vary in the types of decisions they intend to inform, ranging from coverage, access, and pricing decisions to those defining appropriate clinical pathways and to supporting provider-clinician shared decision making. Each of these value frameworks must be evaluated in its own decision context for its own objectives. Existing guidelines for cost-effectiveness analysis emphasize the importance of clearly specifying the perspective from which the analysis is undertaken. Relevant perspectives may include, among others, 1) the health plan enrollee, 2) the patient, 3) the health plan manager, 4) the provider, 5) the technology manufacturer, 6) the specialty society, 7) government regulators, or 8) society as a whole. A valid and informative cost-effectiveness analysis could be conducted from the perspective of any of these stakeholders, depending on the decision context.
引用
收藏
页码:124 / 130
页数:7
相关论文
共 26 条
  • [1] Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]
    Lakdawalla, Darius N.
    Doshi, Jalpa A.
    Garrison, Louis P., Jr.
    Phelps, Charles E.
    Basu, Anirban
    Danzon, Patricia M.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 131 - 139
  • [2] Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5]
    Phelps, Charles E.
    Lakdawalla, Darius N.
    Basu, Anirban
    Drummond, Michael F.
    Towse, Adrian
    Danzon, Patricia M.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 146 - 154
  • [3] Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]
    Willke, Richard J.
    Neumann, Peter J.
    Garrison, Louis P., Jr.
    Ramsey, Scott D.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 155 - 160
  • [4] A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]
    Neumann, Peter J.
    Willke, Richard J.
    Garrison, LouisP., Jr.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 119 - 123
  • [5] A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]
    Garrison, Louis P., Jr.
    Neumann, Peter J.
    Willke, Richard J.
    Basu, Anirban
    Danzon, Patricia M.
    Doshi, Jalpa A.
    Drummond, Michael F.
    Lakdawalla, Darius N.
    Pauly, Mark V.
    Phelps, Charles E.
    Ramsey, Scott D.
    Towse, Adrian
    Weinstein, Milton C.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 161 - 165
  • [6] Reflections on the ISPOR Special Task Force on US Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy
    Garrison, Louis P., Jr.
    Neumann, Peter J.
    Willke, Richard J.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1185 - +
  • [7] Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4]
    Danzon, Patricia M.
    Drummond, Michael F.
    Towse, Adrian
    Pauly, Mark V.
    [J]. VALUE IN HEALTH, 2018, 21 (02) : 140 - 145
  • [8] Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force
    Rothery, Claire
    Strong, Mark
    Koffijberg, Hendrik
    Basu, Anirban
    Ghabri, Salah
    Knies, Saskia
    Murray, James F.
    Schmidler, Gillian D. Sanders
    Steuten, Lotte
    Fenwick, Elisabeth
    [J]. VALUE IN HEALTH, 2020, 23 (03) : 277 - 286
  • [9] Use of pharmacoeconomics information - Report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making
    Drummond, M
    Brown, R
    Fendrick, AM
    Fullerton, P
    Neumann, P
    Taylor, R
    Barbieri, M
    [J]. VALUE IN HEALTH, 2003, 6 (04) : 407 - 416
  • [10] Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force
    Padula, William, V
    Kreif, Noemi
    Vanness, David J.
    Adamson, Blythe
    Rueda, Juan-David
    Felizzi, Federico
    Jonsson, Pall
    IJzerman, Maarten J.
    Butte, Atul
    Crown, William
    [J]. VALUE IN HEALTH, 2022, 25 (07) : 1063 - 1080